Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Daiichi Sankyo
< Previous
1
2
Next >
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
July 03, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
June 05, 2023
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors
June 05, 2023
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA
May 25, 2023
From
Daiichi Sankyo
Via
Business Wire
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
April 20, 2023
From
Daiichi Sankyo
Via
Business Wire
Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials
March 19, 2023
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
March 06, 2023
From
Daiichi Sankyo
Via
Business Wire
TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor
February 01, 2023
From
Daiichi Sankyo
Via
Business Wire
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
January 30, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
December 09, 2022
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
December 08, 2022
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
December 07, 2022
From
Daiichi Sankyo
Via
Business Wire
Data Across Daiichi Sankyo DXd ADC Portfolio at 2022 SABCS Demonstrates Bold Progress in Advancing Treatment for Patients with Breast Cancer
November 21, 2022
From
Daiichi Sankyo
Via
Business Wire
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
October 24, 2022
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
September 11, 2022
From
Daiichi Sankyo
Via
Business Wire
DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
September 10, 2022
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
September 06, 2022
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
August 15, 2022
From
Daiichi Sankyo
Via
Business Wire
Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
August 12, 2022
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
August 11, 2022
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
August 09, 2022
From
Daiichi Sankyo
Via
Business Wire
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
August 08, 2022
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
August 05, 2022
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
July 25, 2022
From
Daiichi Sankyo
Via
Business Wire
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
July 20, 2022
From
Daiichi Sankyo
Via
Business Wire
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
June 13, 2022
From
Daiichi Sankyo
Via
Business Wire
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
June 11, 2022
From
Daiichi Sankyo
Via
Business Wire
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
June 07, 2022
From
Daiichi Sankyo
Via
Business Wire
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
June 03, 2022
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo Showcases Bold Leadership in Oncology with Survival Improvements for Certain Patients with Cancer at ASCO and EHA
May 23, 2022
From
Daiichi Sankyo
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.